US FDA Issues Form 483 With Three Observations for Aarti Drugs Subsidiary
Aarti Drugs Ltd 路 Others (Uncategorized) 路 06 Nov 2026, 10:33 pm
US FDA Issues Form 483 With Three Observations for Aarti Drugs Subsidiary The US FDA inspected the Baddi, Himachal Pradesh formulations manufacturing facility of Aarti Drugs Limited鈥檚 wholly-owned subsidiary, Pinnacle Life Science Private Limited, from 2nd Nov'26 to 6th Nov'26. Upon concluding the inspection, the agency issued Form 483 containing three inspectional observations, none of which pertain to data integrity. Aarti Drugs confirmed that it will work closely with the regulator to resolve all points and stated that the observations have no impact on the company's financial, operational, or other business activities.
Original exchange filing (PDF)
More announcements from Aarti Drugs Ltd
- Intimation of sad demise of Promoter and Chairman Emeritus of the Company 路 16 Nov 2026
- Transcript of Q2&H1 FY27 Earning Conference call 路 11 Nov 2026
- Audio recording for conference call for Analyst and Investors 路 05 Nov 2026
- Investor Presentation for Q2 FY27 路 04 Nov 2026
- Press release on Financial results for Quarter and Half year ended September 2026 路 04 Nov 2026
- Financial Results for the quarter and half year ended September 30, 2026 路 04 Nov 2026
- Aarti Drugs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 04 Nov 2026
- Financial Results for the quarter and half year ended September 30, 2026 路 04 Nov 2026
